Arkolith/Insider Trading/CERO/Form 4

Ehrlich Christopher B

Interim Chairman and CEO, DirectorCERO THERAPEUTICS HOLDINGS, INC. (CERO) · full profile →Form 4 · filed Oct 2, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 25, 2024Option exercise(M)5.3M——5.8M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 30, 2024Disposed to issuer(D)572K—$00
Sep 25, 2024Option exercise(M)275$1000.00$275K0

Transaction Codes

M
Option exercise / conversion
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-24-084830) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML